The CEO, John Sharman and the Non Executive Chairman, David Williams, sold a shit tonne of shares in 2018.  A former director Allan McCallum sold at the same time.  I am unsure whether this was a way to introduce liquidity during a capital raising, or another reason... Still I don't like it.  Shares have not been sold in in other years.???

The CEO only owns 239274 shares...  David Williams, owns 14.67% of the company 9608754 or shares.

Dave Williams is in similar roles with Rate my Agent, Mobile Tyre Shop, & Polynovo. Managing Director Of Kidder Williams Capital Raisings.

John Sharman was Managing Director of CVC Ventures, Vita Life Sciences. Before then CEO at Cyclopharm.

3 other directors are also directors of Polynovo and other companies.

I have not found any reviews on Glassdoor or Seek about the culture within MVP

NPAT increased 81.8% this half year and NoPAT increased 324% between 2018 and 2019.  Isn't that insane growth?

Penthrox sales increased 42%UK, Aus 18%, Europe 35% and there are more countries approving all the time.. the biggest China and the US are yet to approve but Management are ticking their boxes and once that market is cracked the share price will be justified.  

A side note to the Penthrox sales point is that it raises the libido in women (not men).  Which can only be a good thing.

Medical Developments has 3 divisions.  

Pharmaceuticals – the sale of Penthrox® .  This contributes $6652000 revenue, and is their fastest growing segment.

Medical Devices - Asthma Spacers/face masks, CPR flowmeters/masks/regulators... This contributes $4,083,000.00  revenue   

Veterinery - Flow metres/masks /regulators... This contributes $160000.00 revenue.

This half year report highlights some of the sales growth rates in its various divisions.

https://secureservercdn.net/198.71.233.13/c72.d25.myftpupload.com/wp-content/uploads/2020/02/MVP-FY20-Half-Year-Report.pdf

Another way they might create value is with their new manufacturing process (Continuous Flow), which is being developed with the CSIRO.  This lets them use smaller factories, lower costs and speeds up manufacturing when needed, slows it down when required, and produces a higher quality product, rather than the sandardised "batch" way of manufacturing.

Management are also directors in Polynovo (burns), Probiotec (pill and potion packaging for healthcare) and a bunch of other companies in healthcare, realestate, venture capital etc.  this may create possible synergies...

When I worked out their Return on Invested Capital I honestly thought "Why bother researching further" as i thought it should be huge, not negative.  Once include the huge markets yet to be tapped, the current growth rates on all of their products in all regions, and the costs that should be stripped from their balance sheets I think that their profit margins will be huge.

It does pay a dividend also... At the moment its 0.5% which is nothing to brag about....Fast forward 5 years and it could be a great dividend yeild.